Literature DB >> 35382025

Scleroderma-like syndrome associated with pembrolizumab.

Silvia Suárez-Díaz1, Rubén Coto-Hernández1, Carmen Yllera-Gutiérrez1, Carlos Álvarez-Fernández2, Luis Trapiella-Martínez3, Luis Caminal-Montero4.   

Abstract

Entities:  

Year:  2020        PMID： 35382025      PMCID： PMC8922613          DOI： 10.1177/2397198320905192

Source DB:  PubMed          Journal:  J Scleroderma Relat Disord        ISSN： 2397-1983


× No keyword cloud information.
  9 in total

1.  Scleroderma-like syndrome associated with nivolumab treatment in malignant melanoma.

Authors:  Maria Cho; Yumi Nonomura; Yo Kaku; Shuichiro Nakabo; Yuichiro Endo; Atsushi Otsuka; Kenji Kabashima
Journal:  J Dermatol       Date:  2018-06-04       Impact factor: 4.005

2.  Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease.

Authors:  Noha Abdel-Wahab; Mohsin Shah; Maria A Lopez-Olivo; Maria E Suarez-Almazor
Journal:  Ann Intern Med       Date:  2018-07-17       Impact factor: 25.391

Review 3.  Drug-induced Raynaud's phenomenon: beyond β-adrenoceptor blockers.

Authors:  Charles Khouri; Sophie Blaise; Patrick Carpentier; Céline Villier; Jean-Luc Cracowski; Matthieu Roustit
Journal:  Br J Clin Pharmacol       Date:  2016-04-07       Impact factor: 4.335

4.  Relapse of morphea during Nivolumab therapy for lung adenocarcinoma.

Authors:  A Alegre-Sánchez; P Fonda-Pascual; D Saceda-Corralo; E de Las Heras-Alonso
Journal:  Actas Dermosifiliogr       Date:  2016-09-20

5.  Brief Report: Cancer Immunotherapy in Patients With Preexisting Rheumatic Disease: The Mayo Clinic Experience.

Authors:  Michael D Richter; Olga Pinkston; Lisa A Kottschade; Heidi D Finnes; Svetomir N Markovic; Uma Thanarajasingam
Journal:  Arthritis Rheumatol       Date:  2018-02-06       Impact factor: 10.995

6.  Adverse Events Associated with Immune Checkpoint Blockade.

Authors:  Michael A Postow; Matthew D Hellmann
Journal:  N Engl J Med       Date:  2018-03-22       Impact factor: 91.245

7.  Scleroderma Induced by Pembrolizumab: A Case Series.

Authors:  Naiara S Barbosa; David A Wetter; Carilyn N Wieland; Niraj K Shenoy; Svetomir N Markovic; Uma Thanarajasingam
Journal:  Mayo Clin Proc       Date:  2017-06-07       Impact factor: 7.616

Review 8.  Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review.

Authors:  M N Joshi; B C Whitelaw; M T P Palomar; Y Wu; P V Carroll
Journal:  Clin Endocrinol (Oxf)       Date:  2016-04-13       Impact factor: 3.478

9.  Scleroderma-like skin changes induced by checkpoint inhibitor therapy.

Authors:  B Joel Tjarks; Amy M Kerkvliet; Ali D Jassim; Jonathan S Bleeker
Journal:  J Cutan Pathol       Date:  2018-06-12       Impact factor: 1.587
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.